To date, several irreversible and reversible LSD1 inhibitors including GSK2879552, IMG-7289 (Bomedemstat), INCB059872, ORY-1001 (Iadademstat/RG6016/RO7051790), ORY-2001 (Vafidemstat), pargylin, phenelzine, and tranylcypromine (TCP/PCPA)-based inhibitors, alone or in combination with other epi-inhibitors to target multiple modifications, have already shown synergistic antitumor effects in several malignancies [106,107,108,109]. The gene discussed is KDM1A; the disease is cancer.